Author's posts
Pandemic Delays Federal Probe Into Medicare Advantage Health Plans
Government officials want to focus on fighting COVID-19 instead of recouping overcharges that run into the millions.
Some States Are Reporting Incomplete COVID-19 Results, Blurring The Full Picture
Maryland, Ohio and others are reporting only positive tests, which skews tracking and an understanding of how the virus spreads.
Whistleblower Alleges Medicare Fraud At Iconic Seattle-Based Health Plan
A lawsuit against Group Health surfaces as the White House promotes Medicare Advantage for seniors.
KHN Files Lawsuit To Force Feds To Disclose Medicare Advantage Audits
The Freedom of Information Act lawsuit could spur the Centers for Medicare & Medicaid Services to release audits that document up to $650 million in overcharges.
Federal Suit Alleges ‘Staggering’ Urine Drug Testing Fraud At Tennessee Pain Clinics
Tennessee company’s Medicare billings for urine tests were examined by Kaiser Health News in 2017.
Feds Want To Show Health Care Costs On Your Phone, But That Could Take Years
Giving consumers more knowledge about the costs of care has long been desired, but administration officials cautioned it could take two years or more for useful data to appear in a phone app.
Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
Five Things To Know About The Electronic Health Records Mess
The U.S. government claimed that ditching paper medical charts for electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the digital revolution has gone awry.
Feds Settle Huge Whistleblower Suit Over Medicare Advantage Fraud
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
Rudy Giuliani’s Consulting Firm Had Hand In Halting Florida’s Opioid Investigation
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
